Barinthus Biotherapeutics faces Nasdaq listing-rule breach as ADS trading halt nears Sept. 9
Reuters2026/09/01 21:16- Barinthus flagged a Nasdaq continued-listing issue tied to its planned Scheme of Arrangement and related corporate actions.
- England and Wales High Court sanctioned the Scheme of Arrangement and a share premium account capital reduction on Sept. 1, 2026.
- Scheme now expected to become effective Sept. 9, 2026.
- Nasdaq trading in the company’s American depositary shares expected to halt before the open on Sept. 9, 2026.
- Delisting and deregistration plans for the ADSs remain unchanged.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The US Treasury repurchase 'unexpected move' proves fleeting as the long bond sell-off returns; 30-year yields rebound to a pre-intervention high of 5.27%
As of this Tuesday (September 1), the yield on the 30-year U.S. Treasury reached 5.27%, exactly returning to the level before Besant announced the expansion on August 19. Meanwhile, the yield on the 10-year U.S. Treasury, which serves as a key benchmark for various loan rates, has risen by more than 10 basis points compared to that time, hovering around 4.8%.
MongoDB names ex-Salesforce executive Richard Scott SVP for Asia Pacific, Japan
10-Yr Benchmark Govt Yields - Germany vs Other Nations
Crypto prices
More
